Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Anti-InflammatoryClosed to enrollment
KB001-A in people with CF and Pseudomonas aeruginosa
, protocol number KaloBios KB001-05
This study took place at multiple care centres across the U.S. It looked to see whether the use of KB001A in people with CF who have Pseudomonas aeruginosa delays the need for antibiotic drugs.
No mutation requirement
Number of Visits:
Length of Participation:
ObservationalClosed to enrollment
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
, protocol number NARKEW07A0
This study will look at whether using abdominal ultrasounds predicts the progression of liver disease in children with CF.
3 Years to 12 Years
No Mutation Requirement
No FEV1 Limit
Genetic Modifiers of Cystic Fibrosis: Sibling Study
, protocol number NCT00037778
The purpose of the study was to find genetic and environmental factors effecting the variability in nutritional outcomes seen in people with CF.
No age limit
Location: Multiple care centres across the US
Phase 2 study of LAU-7b in adults with CF (APPLAUD)
, protocol number NCT03265288
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and it will use a placebo control.
12 years and older
Anti-InfectiveCompleted with results
OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin
, protocol number NCT02054156 OPTIMIZE-IP-12
This study is taking place at multiple care centers across the US. It will compare the effects of treatment with tobramycin solution for inhalation with and without azithromycin. It is for people with CF who have their first isolation of Pseudomonas aeruginosa from a respiratory culture.
6 Months to 18 Years
No FEV1 limit
Restore CFTR FunctionCompleted with results
Phase 1b safety study of QR-010 in adults with CF
, protocol number NCT02532764 PQ-010-001
This study evaluated the safety and tolerability of the inhaled drug eluforsen in people with CF who have two copies of the F508del CFTR mutation.
18 Years and to 60 Years
Two copies F508del
70% or greater
ObservationalCompleted with results
, protocol number PROSPECT-OB-14
This two-part study is taking place at multiple care centres across the US. It will aim to identify biomarkers that show CFTR function and disease progression. It will also look at the effect of lumacafter/ivacaftor on those who are prescribed treatment.
6 Years and Older
Mucociliary ClearanceClosed to enrollment
Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF)
, protocol number Parion PS-G201
This trail will look at the safety of the drug P-1037 and its effectiveness in combination with the drug hypertonic saline. The trail is estimated to last 5 weeks. It is for people with CF age 12 years and older.
12 Years and Older
40 to 90%
Anti-InfectiveClosed to enrollment
AeroVanc for the treatment of MRSA in people with CF
, protocol number Savara SAV005-02
This study took place at multiple care centres across the US. It looked at the safety and effectiveness of AeroVanc in treating persistent MRSA lung infections in people with cystic fibrosis.
30 to 100%
Mucociliary ClearanceCompleted with results
SHIP: Study of hypertonic saline in preschoolers
, protocol number NCT02378467 SHIP01
This SHIP study evaluated the safety and effectiveness of hypertonic saline (7%) in pre-school children with CF.
3 Years to 5 Years
Less than 99%